Updated and Expanded Guidance on New Pneumococcal Vaccination Strategies for 2025

The landscape of adult pneumococcal vaccination in 2025 continues to evolve rapidly, fueled by regulatory updates, legislative reforms, and groundbreaking vaccine developments. These changes are fundamentally transforming how healthcare providers—pharmacists and clinicians alike—approach immunization, aiming to boost coverage, streamline administration, and ultimately reduce the burden of pneumococcal disease across diverse adult populations. Building on prior guidance, this comprehensive overview highlights the latest developments, their practical implications, and actionable steps for providers to adapt effectively.

---

Key Clinical and Policy Developments in 2025

Simplified and Expanded Vaccination Protocols

Recent updates have notably streamlined pneumococcal vaccination schedules:

• Conjugate Vaccines as Primary Options for Adults ≥65:

  • The CDC’s Advisory Committee on Immunization Practices (ACIP) now endorses PCV15 (Prevnar 15) and PCV20 (Prevnar 20) as primary conjugate vaccines for routine use in adults aged 65 and older.
  • A single-dose of either vaccine serves as sufficient as a standalone for routine immunization, replacing prior multi-step or sequential schedules.
  • This shift is supported by robust clinical evidence demonstrating effective prevention of pneumococcal disease, and it aims to increase vaccination uptake by simplifying decision-making for providers and patients.

• Sequential Vaccination for High-Risk Populations:

  • For immunocompromised and other high-risk groups, the recommendation remains to administer:
    • First, PCV15 or PCV20.
    • Followed by PPSV23.
    • Minimum interval: at least 1 year between PPSV23 doses to optimize immune response and durability.
  • Strict adherence to these timing guidelines is essential to maximize patient protection.

• Safety and Coadministration:

  • New guidance confirms that coadministration of pneumococcal vaccines with influenza and COVID-19 vaccines is safe.
  • This supports bundled vaccination efforts during seasonal campaigns, reducing missed opportunities.
  • Providers should verify compatibility, schedule appropriately, and ensure accurate documentation of all vaccines administered.

• Billing and Reimbursement:

  • Emphasis remains on reviewing insurance benefits, applying correct billing codes, and navigating reimbursements.
  • Efforts continue to reduce out-of-pocket costs, which can significantly improve vaccine acceptance.

---

Policy and Legislative Changes Enhancing Access

2025 has seen significant legislative momentum to expand vaccine access and reduce barriers:

• Insurance Coverage Legislation:

  • Pending laws aim to mandate full insurance coverage of pneumococcal vaccines, eliminating copays.
  • Such policies, highlighted in THU AM News, are designed to reduce financial barriers, especially among underserved populations, thereby promoting health equity.

• Expanded Pharmacist Authority:

  • Legislative reforms empower pharmacists with broader authority to independently administer vaccines.
  • Many pharmacies are updating workflows to pre-verify insurance, implement new billing protocols, and train staff on latest product guidance and coadministration procedures.
  • These reforms accelerate access, particularly in underserved or rural areas, aligning with public health goals to increase adult vaccination rates.

• Public Health Impact:

  • These initiatives support increased coverage, contributing to herd immunity and reduction of disease burden.
  • They are integral to public health strategies emphasizing health equity and improved access.

Regulatory and Vaccine Landscape Developments

The regulatory environment and vaccine innovations in 2025 are active and promising:

• FDA Review of Moderna’s Investigational Seasonal Influenza Vaccine:

  • On February 18, 2026, Reuters reported that the FDA has accepted Moderna’s application for review of its candidate influenza vaccine.
  • If approved, this could revolutionize seasonal flu immunization by offering broader coverage and enhanced efficacy.
  • The potential for coadministration with pneumococcal vaccines would streamline adult immunization schedules, especially during fall campaigns, and significantly increase vaccine uptake.

• Multicomponent Vaccines for Influenza and COVID-19:

  • Advances include multicomponent vaccines combining seasonal influenza, COVID-19, and other respiratory pathogens.
  • These aim to simplify immunization schedules, reduce clinic visits, and maximize respiratory disease protection.
  • Promising candidates are demonstrating efficacy against both influenza and COVID-19, with potential to transform adult vaccination strategies once approved.

• RSV Vaccines for Adults Aged 60+:

  • As reported in AJMC’s Vaccines Compendium, RSV (Respiratory Syncytial Virus) vaccines are now available for adults aged 60 and older.
  • However, waning effectiveness over two seasons, especially among immunocompromised individuals, underscores the need for ongoing surveillance, possible booster doses, and further research to optimize long-term protection.

• Updated COVID-19 Vaccination Recommendations:

  • The American College of Physicians (ACP) recommends that adults aged 65 and older receive updated mRNA COVID-19 vaccines for the 2025–2026 season.
  • This aligns with evidence indicating improved efficacy of bivalent or updated formulations in older populations.
  • Strategies are being refined to coadminister COVID-19 and pneumococcal vaccines, maximizing protection during routine visits.

---

Practical Implications for Healthcare Providers

To implement these updates effectively, pharmacists and clinicians should:

• Routine Screening and Documentation:

  • Review vaccination histories, product types, doses, and timing.
  • Maintain accurate records to identify gaps and optimize opportunities.

• Patient Education and Counseling:

  • Emphasize vaccine safety, benefits, and the importance of coadministration.
  • Address common concerns about multiple vaccines, especially during seasonal campaigns.
  • Highlight legislative efforts that eliminate copays, which can motivate vaccination.
  • Use clear messages to build confidence and counter misinformation.

• Operational Workflow Updates:

  • Adapt protocols to reflect latest eligibility criteria, timing, and billing procedures.
  • Proactively verify insurance coverage, use correct billing codes, and train staff accordingly.
  • Incorporate reminder and recall systems for other vaccines like Tdap, shingles, and hepatitis.

• Community Outreach:

  • Focus on underserved populations.
  • Utilize community engagement and educational materials to increase acceptance and reduce disparities.

• Data Monitoring and Quality Improvement:

  • Use analytics to track vaccination rates, identify gaps, and tailor strategies.

---

Current Status and Future Outlook

The convergence of clinical updates, policy reforms, and vaccine innovations offers a remarkable opportunity to significantly enhance adult pneumococcal vaccination rates:

• The postponement of the CDC’s ACIP meeting—originally scheduled but recently canceled without rescheduling—delays formal updates to official recommendations. In the interim, providers should continue monitoring CDC communications and prepare to adapt practices once new guidance is issued.

• The ongoing regulatory review of promising vaccines, including Moderna’s flu candidate and multicomponent formulations, holds the potential to revolutionize adult respiratory immunization.

• Legislative efforts to expand pharmacist authority and mandate insurance coverage are critical levers to improve access, especially for vulnerable populations.

• Addressing disparities through pharmacy-based programs and community outreach will be essential in achieving equitable immunization coverage.

In summary, 2025 is a pivotal year for adult respiratory vaccination. The simplification of schedules, expansion of vaccine options, and advances in vaccine technology—combined with policy reforms—are setting the stage for greater protection against pneumococcal disease and other respiratory illnesses. Healthcare providers must stay informed, flexible, and proactive to maximize these opportunities and protect public health effectively.

---

As public health leaders emphasize, “Consistent patient counseling on respiratory vaccines—including influenza, COVID-19, and pneumococcal vaccines—is essential to improving coverage and protecting vulnerable groups.” Ongoing education, collaboration, and public engagement remain critical to achieving these goals in 2025 and beyond.